Search

Displaying results 3211 - 3220 of 10000 in total
  1. Drug

    Lumefantrine

    go.drugbank.com/drugs/DB06708
    ApprovedInvestigational

    Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy. … </i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.

  2. Drug

    INM005

    go.drugbank.com/drugs/DB16499
    Investigational

    INM005 was under investigation in clinical trials for the treatment of COVID-19. It was studied for pharmacokinetics, efficacy, and safety in a completed trial (NCT04494984).

  3. Drug

    Ragweed pollen extract

    go.drugbank.com/drugs/DB05368
    ApprovedWithdrawn

    Ragweed pollen extract has been developed by Curalogic. The company has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy. … While traditional disease-modifying immunotherapeutics are administered by subcutaneous injection, Curalogic has developed a more convenient orally administered drug.

  4. Drug

    Dehydroascorbic acid

    go.drugbank.com/drugs/DB08830
    Experimental

    Dehydroascorbic acid as well as ascorbic acid are both termed Vitamin C, but the latter is the main form found in humans. … In the body, both dehydroascorbic acid and ascorbic acid have similar biological activity as antivirals but dehydroascorbic acid also has neuroprotective effects.

  5. Drug

    Parecoxib

    go.drugbank.com/drugs/DB08439
    ApprovedInvestigational

    It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib (Celebrex) and rofecoxib (Vioxx). … A letter of non-approval for parecoxib was issued by the FDA in 2005.

    Synonyms: N-((p-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)propionamideProducts: PARECOXB parecoxib (as sodium) 40mg powder for solution for injection
  6. Drug

    V24343

    go.drugbank.com/drugs/DB05201
    Investigational

    The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.

  7. Drug

    Liposomal prostaglandin E1

    go.drugbank.com/drugs/DB05391
    Investigational

    Liposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent. … The liposomal formulation of PGE-1 changes the drug’s dynamics and improve its therapeutic index in ways that PGE-1 alone could not achieve.

    Synonyms: Liposomal prostaglandin E1
  8. Drug

    Opaganib

    go.drugbank.com/drugs/DB12764
    Investigational

    [L27436] This drug has potential anticancer, anti-inflammatory, and antiviral activities, with potential applications in oncology, inflammation, the gastrointestinal system, and COVID-19. … Opaganib, also known as ABC294640, is a selective [sphingosine kinase-2 (SK2)](https://go.drugbank.com/polypeptides/Q9NRA0) inhibitor that is orally administered.

  9. Drug

    N-(2-Aminoethyl)-1-aziridineethanamine

    go.drugbank.com/drugs/DB15643
    Experimental

    First described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease

    Synonyms: N-(2-((2-Aminoethyl)amino)ethyl)aziridine, N-(2-aminoethyl)-1 aziridine-ethanamineCategories: Agents Acting on the Renin-Angiotensin System
  10. Drug

    Chlormadinone acetate

    go.drugbank.com/drugs/DB15903
    ApprovedWithdrawn

    In the US, chlormadinone acetate was formerly marketed as a component of the combination drug products Estalor-21 and C-Quens. … However, the use of these drugs was associated with the development of mammary tumors in dogs. In 1972, the FDA withdrew its approval for the use of chlormadinone acetate in all products.

    Mixtures: LUTORAL-E